z-logo
Premium
Effect of inhaled corticosteroids on risk of development of cataract: a meta‐analysis
Author(s) -
Uboweja Anup,
Malhotra Samir,
Pandhi P.
Publication year - 2006
Publication title -
fundamental and clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.655
H-Index - 73
eISSN - 1472-8206
pISSN - 0767-3981
DOI - 10.1111/j.1472-8206.2006.00397.x
Subject(s) - medicine , meta analysis , odds ratio , confidence interval , publication bias , number needed to harm , relative risk , hazard ratio , study heterogeneity , medline , number needed to treat , political science , law
The objective of this study was to quantify the risk of cataract among users of inhaled corticosteroids (ICS). Studies that examined the association of ICS use with risk of cataract were identified through computerized (MEDLINE, EMBASE), manual searches using Index Medicus, and checking cross‐references to recover all published articles and scientific session abstracts. Pooled odds ratio (OR) with 95% confidence intervals (CI) were estimated using two methods, fixed effects Mantel–Haenszel model and random effects DerSimonian–Laird model. Four studies satisfied all the inclusion/exclusion criteria and were included in the analysis. The pooled OR (95% CI) by the Mantel–Haenszel method was 1.48 (1.39–1.57) and by the DerSimonian–Laird method was 1.48 (1.30–1.68). The test for heterogeneity was not significant. A total number of nine negative studies would be required to make the results of our meta‐analysis non‐significant. Number needed to harm is 16 with 95% CI of 13–19. Contrary to popular belief, inhaled ICS may be associated with systemic side effects like cataract as shown by this meta‐analysis. The risk of increased cataract shown in our analysis needs to be weighted against the benefits of ICS. Further evaluations are required to clarify the causal association between the dosage and duration of drug use.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here